MGC Pharmaceuticals Ltd to become first medicinal cannabis company listed on London Stock ExchangePosted by On


MGC Pharma will maintain a dual LSE and ASX listing to significantly broaden the company’s international profile and provide direct access to UK and European institutional and other investors.

() (FRA:H5O) (LON:MXC) is set to become the first medicinal cannabis company to be admitted to the main market of the London Stock Exchange (LSE) on Tuesday, February 9. 

This follows a strongly supported £6.5 million (around A$12 million) share placement led by leading UK institutional fund managers and supported by UK family office and professional high net worth investors. 

The binding commitments were obtained following an announcement of the company’s proposed LSE listing on February 2. 

“Already seeing the benefits of this decision”

Co-founder and MD Roby Zomer said: “This is something we have been working towards for over 18 months, realising our strategic ambition to be closer to our operations in Europe with greater access to key UK and European strategic investors.

“We are already seeing the benefits of this decision, with the strong show of support from a number of leading UK institutional funds and sophisticated investors for the placing, which was significantly oversubscribed, to coincide with our LSE listing.

“The funds will primarily be used to support the company’s growth ambitions and key clinical research programs for our leading…

Original Author Link click here to read complete story..

MGC Pharma will maintain a dual LSE and ASX listing to significantly broaden the company’s international profile and provide direct access to UK and European institutional and other investors.

() (FRA:H5O) (LON:MXC) is set to become the first medicinal cannabis company to be admitted to the main market of the London Stock Exchange (LSE) on Tuesday, February 9. 

This follows a strongly supported £6.5 million (around A$12 million) share placement led by leading UK institutional fund managers and supported by UK family office and professional high net worth investors. 

The binding commitments were obtained following an announcement of the company’s proposed LSE listing on February 2. 

“Already seeing the benefits of this decision”

Co-founder and MD Roby Zomer said: “This is something we have been working towards for over 18 months, realising our strategic ambition to be closer to our operations in Europe with greater access to key UK and European strategic investors.

“We are already seeing the benefits of this decision, with the strong show of support from a number of leading UK institutional funds and sophisticated investors for the placing, which was significantly oversubscribed, to coincide with our LSE listing.

“The funds will primarily be used to support the company’s growth ambitions and key clinical research programs for our leading…



Source link

News

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.